Californian cell therapy company Orca Bio has announced positive results from the pivotal Phase III Precision-T study of d, its lead investigational allogeneic T-cell immunotherapy, acute myeloid ...

Despite a challenging year, FibroGen Inc (FGEN) focuses on promising drug developments and cost reductions to bolster future growth.

Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...

The myelofibrosis drug landscape has become more crowded since Syntara decided to focus on the disease in 2020, but the ...

Announced sale of FibroGen China to AstraZeneca for a total consideration of approximately $160 millionTransaction expected to close by ...

Orca-T improved 1-year survival without severe graft-vs-host disease compared with standard transplant in the Precision-T ...

Announced sale of FibroGen China to AstraZeneca for a total consideration of approximately $160 million Transaction expected to close by mid-2025 Upon close of sale of FibroGen China, cash runway exte ...

A patient has died while taking a closely watched gene therapy for muscular dystrophy. Sarepta Therapeutics announced the death Tuesday morning, sending the company's shares plummeting in morning ...

Northwestern Medicine investigators have identified novel mechanisms regulating the development of the spinal column during ...

After Hiding My Undiagnosed Neurological Condition for Decades, I Finally Found Answers A personal quest and progress in brain science finally put a name on baffling behaviors ...

For anyone who feels stiffness in their neck that radiates down to their arms with numbness or tingling or weakness in the ...

Learning from examples like congenital heart disease and cystic fibrosis can help health systems and clinicians prepare to care for an influx of patients with neuromuscular diseases as they reach ...